Dexlansoprazole DDR

Product overview

Dexlansoprazole DDR Pellets – Dual Delayed-Release Technology for Sustained Acid Control. Rraynex’s dexlansoprazole dual delayed-release (DDR) pellets are engineered to deliver sequential release pulses, ensuring extended proton pump inhibition (PPI) across the entire 24-hour dosing interval. Manufactured with precision-controlled dual enteric coating layers, these pellets achieve predictable pharmacokinetics and enhanced therapeutic consistency for gastroesophageal reflux disease (GERD) and related acid disorders. Overview: Dexlansoprazole, the R-enantiomer of lansoprazole, is a next-generation proton pump inhibitor that suppresses gastric acid secretion more effectively by providing two distinct release phases. Our pelletized DDR system uses advanced layering techniques to deliver a delayed release at two pH thresholds, ensuring prolonged acid suppression and improved patient adherence through once-daily dosing. Key Features & Benefits: • Dual-Phase Release: Two enteric coatings with unique dissolution thresholds enable sequential drug delivery for sustained efficacy. • Consistent Pellet Engineering: Optimized size distribution and surface finish for smooth capsule filling and uniform dispersion. • Stability and Purity: Manufactured under controlled conditions with real-time monitoring of assay, solvent residues, and moisture content. • Regulatory Compliance: Nitrosamine risk evaluation, comparative dissolution data, and multi-pH release profiles provided per batch. • Climate-Validated Durability: Stability studies simulate both temperate and tropical zones to ensure coating integrity during storage and transport. • Application Versatility: Suitable for hard gelatin capsules, sachets, or multiparticulate tablets requiring pH-triggered release. Technical Specifications: • API: Dexlansoprazole (R-enantiomer of Lansoprazole) • Assay: 98.0–102.0% • Pellet Size Range: 500–1000 μm (customizable) • Release Mechanism: Dual Delayed-Release (DDR) enteric coatings at pH 5.5 and pH 7.0 • Loss on Drying: ≤1.5% • Packaging: Moisture-barrier drums, foil-lined pouches, or nitrogen-purged containers for long-haul stability • Storage: Store below 25°C, protected from moisture and light. Applications: • Pharmaceutical manufacturers formulating gastro-resistant or dual delayed-release products. • CDMOs and R&D teams developing differentiated PPI formulations for GERD management. • Exporters and B2B suppliers focused on high-stability enteric-coated APIs and pellets. Educational Insight: Dexlansoprazole belongs to the proton pump inhibitor (PPI) class, reducing acid production in the stomach by blocking the H+/K+ ATPase enzyme system. The dual delayed-release (DDR) technology allows two separate pulses of drug release—one in the proximal small intestine and another in the distal region—extending acid suppression duration and improving symptom control for patients with reflux and erosive esophagitis. SEO Keywords: dexlansoprazole pellets, DDR pellets, dual delayed-release pellets, dexlansoprazole PPI, gastro resistant pellets, acid reflux pellets, GERD treatment pellets, enteric coated dexlansoprazole, pharmaceutical pellets manufacturer, dexlansoprazole API supplier, PPI raw material exporter Usage Note: For pharmaceutical manufacturing and educational use only. Dexlansoprazole-containing medications should be formulated and administered under medical supervision. Manufacturers are responsible for validating formulations per pharmacopeial and regulatory guidelines before commercial release.